bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.

bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Bluebird (BLUE) Down 6.2% Since Last Earnings Report: Can It Rebound?

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ: BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel.

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the FDA Cellular, Tissue and Gene Therapies Advisory Committee Meeting to review elivaldogene autotemcel (eli-cel) for early active cerebral adrenoleukodystrophy (CALD) in patients without a matched sibling donor and betibeglogene autotemcel (beti-cel) for the treatment of people with β-thalassemia

bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting

ACADIA Pharma

Axsome Therapeutics

Bristol-Myers

Moderna

Rhythm Pharmaceuticals

Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead of These June Catalysts appeared first on InvestorPlace.

6 Biotech Stocks to Buy Now Ahead of These June Catalysts

Provention Bio Inc

2 High-Risk, High-Reward Stocks for Contrarian Investors

bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.

bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of -31.75% and 86.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the first quarter ended March 31, 2022, and shared recent operational progress. “For more than a decade, bluebird bio has helped chart the path for the field of gene therapy and today, we are closer than ever before to realizing our mission of bringing potentially curative gene therapies to patients and their families,” said Andrew O

bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress

Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022. FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to receive Priority Review Vouchers which it could sell for upwards of over $100 million each.

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

Vertex Pharmaceuticals

Biotech stocks have been successful in going public without revenues because the story of a pharmaceutical firm gaining FDA approval for a new drug is attractive to many investors.

One Biotech Stock to Hold; Another to Dump Right Now

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Bluebird Bio (BLUE) Report Negative Q1 Earnings? What You Should Know

With no stable stream of income, bluebird bio (BLUE) faces a severe cash crunch. Moreover, the FDA extending the review period of its two regulatory filings also adds fuel to this fire.

Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?

Investors recently raised bearish bets that this cash burning biotech will burn through what remains. Shares have fallen 24% in the two weeks since it announced cost cuts.

Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash

The expected upcoming catalysts might not be all that the company needs.

Is Bluebird Bio a Buy?

Amylyx Pharmaceuticals

Biogen

Gilead Sciences

TG Therapeutics

If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock price but also a company's future.

5 Key FDA Decisions Could Affect Drug Stocks

Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. The post Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks appeared first on InvestorPlace.

Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks

bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.

bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn

Insider identified Bluebird Bio last month as one of 13 biotechs in a dangerous financial position.

Gene-therapy biotech Bluebird Bio is set to lay off 30% of the company after warning it could struggle to survive through 2022

Shares of Bluebird bio Inc. BLUE, +5.44% fell 0.6% in premarket trading Tuesday, after the gene therapies company announced a restructuring save it $160 million over the next two years but cost 30% of its employees their jobs. With 518 full-time employees as of Jan. 31, that could mean about 155 employees will be laid off.

Bluebird bio to lay off nearly one-third of its employees as part of restructuring

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Following a review of its strategic priorities, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is initiating a comprehensive restructuring intended to deliver up to $160 million in cost savings over the next two years. bluebird intends to sharpen its focus on near-term catalysts, including anticipated FDA approvals for its gene therapies for beta-thalassemia and cerebral adrenoleukodystrophy in 2022, and the potential submission of a biolog

bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US

Beyond Meat

DXC Technology

Gap Inc

Wall Street analysts are constantly releasing and updating reports on stocks across their respective coverage universes.

5 Stocks That Wall Street Hates This Week

bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.

bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes

The biotech's financial position has some investors worried.

Why Bluebird Bio Stock Is Sinking Today

Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of approximately $442 million. The full-year 2022 cash burn is expected to be less than $400 million.

News for bluebird bio Stock (BLUE)